Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAlaska Medicaid Botox Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentAlaska MedicaidPolicy N/A

    Botulinum toxin (Botox) prior authorization — multiple indications

    Customize your policy alerts

    Sign up for all Alaska Medicaid policy alerts

    Know when Alaska Medicaid releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and criteria governing prior authorization requests for botulinum toxin (Botox) for Alaska Medicaid members across multiple indications (e.g., chronic migraine, spasticity, hyperhidrosis, dystonias, bladder conditions). Affects prescribers, physician-administered drug billing, and pharmacy requests to Alaska Medicaid.

    Policy Summary
    PayerAlaska Medicaid
    PolicyBotulinum toxin (Botox) prior authorization — multiple indications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the prior authorization form to the correct HMS or pharmacy fax and include required documentation (procedure codes, date of service, ICD-10, and supporting clinical notes).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥12
    indications listed
    2physician fax contacts
    2 trialsbladder trial req
    ≥2 classesmigraine trial req

    Coverage Criteria by Indication

    Axillary Hyperhidrosis

    Axillary Hyperhidrosis covered when ALL of the following are met

    Axillary Hyperhidrosis: Topical agents are not controlling the condition.
    Axillary Hyperhidrosis: Hyperhidrosis Disease Severity Scale (HDSS) score > 3.HDSM > 3

    Blepharospasm

    Blepharospasm covered when ALL of the following are met

    Blepharospasm: Member is unable to open eyelid(s) or is functionally blind due to dystonia.
    Blepharospasm: Ordering provider is a neurologist or ophthalmologist; if not, submit plan of care and chart notes from the ordering MD.

    Cervical Dystonia

    Cervical Dystonia covered when ALL of the following are met

    Cervical Dystonia: Purpose of treatment is to reduce the severity of abnormal head position and neck pain.

    Chronic Migraine

    Chronic Migraine covered when ALL of the following are met

    Chronic Migraine Initial: Patient has headaches ≥ 15 days per month lasting ≥ 4 hours per day.>=15 days/month
    Chronic Migraine Initial: Trial with inadequate response, intolerance, or contraindication to at least 2 migraine prophylaxis classes (e.g., anticonvulsants, beta blockers).>=2 prophylaxis classes tried
    Chronic Migraine Initial: Ordering provider is a neurologist; if not, submit plan of care and chart notes from the ordering MD.
    Chronic Migraine Renewal: Headache frequency decreased by at least 2 headache days from baseline in the previous month (renewal criterion).

    Chronic Sialorrhea

    Chronic Sialorrhea covered when ALL of the following are met

    Chronic Sialorrhea: Patient tried and failed one first-line agent (benztropine, oral hyoscyamine, or glycopyrrolate) or has a contraindication to all of them.1 failed agent or contraindication

    Neurogenic Detrusor Overactivity

    Neurogenic Detrusor Overactivity (NDO) covered when ALL of the following are met

    Neurogenic Detrusor Overactivity: Documented symptoms of detrusor overactivity.
    Neurogenic Detrusor Overactivity: Trial of 2 different pharmacologic treatments for at least 60 days with documentation of inadequate response or a justifiable contraindication to oral antimuscarinics or oral β3-adrenergic receptor agonists (e.g., oxybutynin, tolterodine, mirabegron).2 trials x >=60 days

    Examples: oxybutynin, tolterodine, mirabegron

    Overactive Bladder

    Overactive Bladder covered when ALL of the following are met

    Overactive Bladder: Documented moderate to severe symptoms of urge urinary incontinence, urgency, and frequency.
    Overactive Bladder: Documented behavioral therapy trials.
    Overactive Bladder: Trial of 2 different pharmacologic treatments for at least 60 days with documentation of inadequate response or a justifiable contraindication to oral antimuscarinics or oral β3-adrenergic receptor agonists (e.g., oxybutynin, tolterodine, mirabegron).2 trials x >=60 days

    Spasticity / Upper Limb Spasticity

    Spasticity covered when ALL of the following are met

    Spasticity General: Spasticity is refractory to oral medication.
    Upper Limb Spasticity (Cerebral Palsy): Spasticity secondary to cerebral palsy (form asks to confirm) and refractory to oral medication.

    Form asks if spasticity is secondary to cerebral palsy; question defaults to 'No' for CP on the upper-limb specific section

    Urinary Incontinence Secondary to Detrusor Overactivity

    Urinary Incontinence Secondary to Detrusor Overactivity covered when ALL of the following are met

    Urinary Incontinence (Secondary): Documented symptoms of detrusor overactivity.
    Urinary Incontinence (Secondary): Trial of 2 different pharmacologic treatments for at least 60 days with documentation of inadequate response or a justifiable contraindication to oral antimuscarinics or oral β3-adrenergic receptor agonists (e.g., oxybutynin, tolterodine, mirabegron).2 trials x >=60 days

    For any request to use botulinum toxin for an indication that is not an FDA‑approved use (non‑cosmetic), the form requires submission of supporting medical literature and a letter of medical necessity that documents the diagnosis and prior therapies. This additional documentation is necessary to allow clinical review of non‑FDA‑approved indications and must be attached to the prior authorization request.

    Incomplete or missing additional documentation for non‑FDA‑approved indications will delay or prevent authorization; ensure the literature and letter explicitly describe the prior treatments tried and the rationale for botulinum toxin in this specific patient.

    Billing and Coding Requirements

    Required billing identifiersmixed
    NDCNDC field present for pharmacy-dispensed product
    Procedure CodeProcedure Code field required for physician providers (J-code billing)
    ICD-10ICD-10 diagnosis code field required
    Chronic migraine frequency reduction — renewal threshold
    Renewal requirementHeadache frequency must have decreased by at least 2 headache days from baseline in the previous month for renewal authorization
    Initial coverage frequency thresholdInitial diagnosis requires headaches ≥ 15 days per month lasting ≥ 4 hours
    Prior prophylaxis requirementPatient must have tried and had inadequate response, intolerance, or contraindication to at least 2 migraine prophylaxis classes (e.g., anticonvulsants, beta blockers)
    Ordering providerOrdering neurologist preferred; if not the ordering neurologist, submit plan of care and chart notes

    What Providers Must Do

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Complete and fax the Alaska Medicaid Botox® Prior Authorization Form to the appropriate recipient based on provider type: physician providers (office supply/J‑code billing) fax to HMS at (907) 644-8131; pharmacy providers fax to (888) 603-7696. This authorization request does not ensure eligibility or guarantee payment. Verify member Medicaid eligibility before submitting.

    • Fax numbers: HMS (907) 644-8131 — physicians (J‑code); Pharmacy: (888) 603-7696
    • Form available on Alaska Medicaid's Medication Prior Authorization website
    Step Therapy

    Bladder/Urinary Step Therapy Requirements

    Step therapy for bladder/urinary indications requires documentation of prior trials. For Neurogenic Detrusor Overactivity and Overactive Bladder, patient must have tried two different pharmacologic treatments for at least 60 days with documentation of inadequate response or a justifiable contraindication to oral antimuscarinics or oral β3‑adrenergic receptor agonists (examples: oxybutynin, tolterodine, mirabegron). For Overactive Bladder, documented behavioral therapy trials are also required and symptoms must be moderate to severe.

    Background

    Botulinum toxin (Botox) is used across multiple neurologic and non‑neurologic conditions covered on the Alaska Medicaid prior authorization form, including spasticity, dystonias (e.g., blepharospasm, cervical dystonia), chronic migraine prophylaxis, hyperhidrosis, chronic sialorrhea, and bladder disorders such as neurogenic detrusor overactivity and overactive bladder. The form collects key clinical details—primary diagnosis, ICD‑10 code, patient age group, and indication‑specific questions—to support medical necessity determinations. For non‑FDA uses, the form additionally requires referenced literature and a letter of medical necessity that lists prior therapies and the clinical justification for treatment.

    Definitions and Non-standard Uses

    Non‑FDA‑approved indication — documentation requirement
    DefinitionAny indication listed that is not an FDA‑approved use — requires medical literature and a letter of medical necessity including previous therapies and diagnosis
    Required attachmentsInclude medical literature supporting the non‑FDA use and a letter of medical necessity listing previous therapies and diagnosis
    Form noteThe prior authorization form includes a checkbox to indicate non‑FDA‑approved indications and prompts for the required documentation
    Policy Summary
    PayerAlaska Medicaid
    PolicyBotulinum toxin (Botox) prior authorization — multiple indications
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionComplete and fax the prior authorization form to the correct HMS or pharmacy fax and include required documentation (procedure codes, date of service, ICD-10, and supporting clinical notes).
    SourceLink
    On This Page
    Coverage Criteria by IndicationBilling and Coding RequirementsWhat Providers Must DoBackgroundDefinitions and Non-standard Uses
    >=2 day reduction

    Used for renewal authorization only

    • Two pharmacologic trials required — duration: at least 60 days each
    • Acceptable agents include oral antimuscarinics or oral β3‑adrenergic agonists (e.g., oxybutynin, tolterodine, mirabegron)
    • Behavioral therapy documentation required for Overactive Bladder
    • Document presence of moderate to severe urge urinary incontinence, urgency, and frequency for Overactive Bladder requests
    Documentation Required

    Required Documentation and Attachments

    Required documentation and attachments must accompany the prior authorization form. Physician requests must include procedure codes, date of service, and ICD‑10 diagnosis codes. Attach supporting documentation such as treatment history (dates and outcomes of prior pharmacologic therapies), behavioral therapy records when applicable, clinical notes describing symptoms, and any Letters of Medical Necessity or supporting literature.

    • Procedure codes and date of service (required for physician/J‑code billing)
    • ICD‑10 diagnosis code(s)
    • Documentation of prior pharmacologic trials (agents used, start/stop dates, reason for discontinuation or inadequate response)
    • Behavioral therapy documentation when applicable (for Overactive Bladder)
    • Letters of Medical Necessity or supporting clinical literature, if applicable
    Denial Risk

    Incomplete Request Denial Risk

    Incomplete requests will be denied until all required information is received. Ensure all required fields on the form are completed (including prescriber and pharmacy information, drug name/NDC/strength, dosage, quantity/day supply, and attestation with prescriber signature and date).

    • Complete prescriber information (name, NPI, specialty, phone, fax, group ID)
    • Complete pharmacy information when pharmacy provider (pharmacy name, NPI, phone, fax, NDC, strength, dosage, quantity, day supply)
    • Include attestation with prescriber signature and date
    • Incomplete requests will be denied